Post Marketing Surveillance of BI-Sifrol® (Pramipexole). Special Survey on Patients With Parkinson's Disease and Renal Dysfunction

Trial Profile

Post Marketing Surveillance of BI-Sifrol® (Pramipexole). Special Survey on Patients With Parkinson's Disease and Renal Dysfunction

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Nov 2013

At a glance

  • Drugs Pramipexole (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 12 Feb 2009 Actual initiation date (Feb 2004) added as reported by ClinicalTrials.gov.
    • 09 Feb 2009 Planned number of patients changed from 100 to 107 as reported by ClinicalTrials.gov.
    • 25 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top